MARKET

RCKT

RCKT

ROCKET PHARMACEU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

40.54
-0.40
-0.98%
Opening 14:53 05/14 EDT
OPEN
41.00
PREV CLOSE
40.94
HIGH
42.10
LOW
39.95
VOLUME
267.51K
TURNOVER
--
52 WEEK HIGH
67.48
52 WEEK LOW
16.53
MARKET CAP
2.57B
P/E (TTM)
-14.9286
1D
5D
1M
3M
1Y
5Y
Insider Trends: Rocket Pharmaceuticals Insider Extends 90-Day Selling Trend
MT Newswires · 22h ago
Rocket Pharmaceuticals Announces Positive Data From RP-L102, RP-L201 Gene Therapy Programs
Benzinga · 1d ago
BRIEF-Rocket Pharmaceuticals Presents Positive Clinical Data At Annual Meeting Of The American Society of Gene and Cell Therapy
reuters.com · 1d ago
Rocket Pharma announces positive effect in early-stage trials for rare genetic diseases
Rocket Pharmaceuticals (RCKT) announced clinical data from three of its gene therapy programs aimed at rare hereditary diseases mainly impacting children: Fanconi Anemia ((FA)), Leukocyte Adhesion Deficiency-I ((LAD-I)), and Pyruvate Kinase Deficiency
Seekingalpha · 1d ago
Rocket Pharma Presents Clinical Data From Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency Programs at Meeting of American Society of Gene and Cell Therapy: Showed Evidence Of Prelim. Engraftment In At Least 6 Of 9 Patients
—RP-L102 for Fanconi Anemia Shows Evidence of Preliminary Engraftment in at Least Six of Nine Patients— — RP-L201 for LAD-I Leads to Durable CD18 Expression, Improved Skin Lesions, and Consistent
Benzinga · 1d ago
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24th Annual Meeting of the American Society of Gene and Cell Therapy
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces positive clinical data from its Fanconi Anemia (FA), Leukocyte Adhesio...
Business Wire · 1d ago
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 2d ago
WestRock Co. stock outperforms market on strong trading day
Shares of WestRock Co. rose 1.74% to $60.72 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...
marketwatch.com · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RCKT. Analyze the recent business situations of ROCKET PHARMACEU through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RCKT stock price target is 72.40 with a high estimate of 100.00 and a low estimate of 56.00.
EPS
Institutional Holdings
Institutions: 215
Institutional Holdings: 66.98M
% Owned: 105.65%
Shares Outstanding: 63.40M
TypeInstitutionsShares
Increased
51
7.19M
New
60
5.18M
Decreased
49
3.48M
Sold Out
9
1.98M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.92%
Pharmaceuticals & Medical Research
+1.18%
Key Executives
Chairman/Director
Roderick Wong
President/Chief Executive Officer/Director
Gaurav Shah
Chief Financial Officer
Carlos Garcia-Parada
Chief Operating Officer
Kinnari Patel
Senior Vice President - Finance
Kamran Alam
Chief Accounting Officer/Vice President - Finance/Controller/Treasurer
John Militello
Other
Jonathan Schwartz
Director
David Southwell
Independent Director
Elisabeth Bjork
Independent Director
Carsten Boess
Independent Director
Pedro Granadillo
Independent Director
Gotham Makker
Independent Director
Naveen Yalamanchi
No Data
  • All
  • Financials
  • Insiders
More
About RCKT
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Company’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Company’s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a genetic disease that leads to bone marrow failure and potentially cancer. Its additional pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). The Company is also developing an AAV-based gene therapy program for pediatric heart failure indication, Danon disease.

Webull offers kinds of Rocket Pharmaceuticals Inc stock information, including NASDAQ:RCKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCKT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RCKT stock methods without spending real money on the virtual paper trading platform.